| Baber WJ, Neeff M
Ciproxin HC eardrops application for funding--and response from PHARMAC. [Letter]
N Z Med J 2008 Sep 5; 121(1281):111-4.
Full Citation | Find Related Articles |
| Simpson A
What's happening in PHARMAC--where do all the submissions go? On the trail of gemcitabine. [Journal Article]
N Z Med J 2005 Nov 11; 118(1225):U1733.
Abstract | Full Citation | Find Related Articles |
| Grocott R, Metcalfe S
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. [Journal Article]
N Z Med J 2005 Oct 7; 118(1223):U1690.
Abstract | Full Citation | Find Related Articles |
| Raftery JP
Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. [Journal Article]
Med J Aust 2008 Jan 7; 188(1):26-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Whyte K
PHARMAC not funding some treatments for rare, life-threatening diseases: bosentan as an example. [Journal Article]
N Z Med J 2005 Nov 25; 118(1226):U1759.
Abstract | Full Citation | Find Related Articles |
| Rasiah D
More from PHARMAC on temozolomide: feedback needed. [Comment, Letter]
N Z Med J 2006; 119(1230):U1896.
Full Citation | Find Related Articles |
| Metcalfe S, Evans J, Moodie P
PHARMAC responds on long-acting insulin analogues. [Comment, Letter]
N Z Med J 2005 Oct 28; 118(1224):U1716.
Full Citation | Find Related Articles |
| Metcalfe S, Wilkinson T, Rasiah D
PHARMAC responds on agents to prevent osteoporotic fractures. [Comment, Letter]
N Z Med J 2006; 119(1230):U1895.
Full Citation | Find Related Articles |
| Metcalfe S, Rasiah D, Dougherty S
PHARMAC responds on treatments for pulmonary arterial hypertension. [Comment, Letter]
N Z Med J 2005 Dec 16; 118(1227):U1805.
Full Citation | Find Related Articles |
  |
